**The Corporate Organization**

In 1996 Chromogenix became a part of the Instrumentation Laboratory group. Instrumentation Laboratory is a worldwide corporation providing laboratory reagents, instruments and services in a number of key diagnostic areas, including Hemostasis, Critical Care and Clinical Chemistry.

**R&D, Manufacturing, Marketing**

Research, development and production of all reagent products is based in the Instrumentation Laboratory plant located in Orangeburg NY, USA, where all Chromogenix brand products are manufactured. Located in Milan, Italy, the Chromogenix Marketing Group manages all aspects of the business and is the heart of the technical support network.

**Quality Statement**

At Chromogenix, we believe that the quality of our products and services are critical, not only for today's good reputation, but also for tomorrow's success. We want our customers to know that:

- Chromogenix' name represents a high quality of service, which is integral to the company's concept of total quality.
- Chromogenix constantly strives to manufacture quality products that our customers will find useful, effective and reliable.
- Chromogenix' products reflect not only the customer's needs but also local regulatory requirements.
- Chromogenix' approach to development, manufacturing and marketing is governed by ethical business principles.
- Chromogenix emphasises the importance of a high level of quality consciousness among staff at all levels within the organisation.

Chromogenix' quality policy extends not only to our products but also to our organisation, the way we work, and the service we provide to our customers.
You will get much more information on the ongoing activities of our company, new product releases, research methods and articles, and have easy access to other interesting web sites.
<table>
<thead>
<tr>
<th>Reagent Kits</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Cardiolipin</td>
<td>12</td>
</tr>
<tr>
<td>Antithrombin</td>
<td>5</td>
</tr>
<tr>
<td>APC™ Resistance</td>
<td>6</td>
</tr>
<tr>
<td>APC™ Resistance V</td>
<td>7</td>
</tr>
<tr>
<td>Factor VII</td>
<td>9</td>
</tr>
<tr>
<td>Factor VIII</td>
<td>10</td>
</tr>
<tr>
<td>Heparin</td>
<td>11</td>
</tr>
<tr>
<td>Plasmin Inhibitor</td>
<td>13</td>
</tr>
<tr>
<td>Plasminogen</td>
<td>13</td>
</tr>
<tr>
<td>Protein C</td>
<td>8</td>
</tr>
<tr>
<td>Protein S free</td>
<td>8</td>
</tr>
<tr>
<td>Calibrators and Controls</td>
<td>14</td>
</tr>
<tr>
<td>Bioreagents</td>
<td>15</td>
</tr>
<tr>
<td>Chromogenic Substrates</td>
<td>16-17-18</td>
</tr>
<tr>
<td>Schematic View of the Haemostatic System</td>
<td>19</td>
</tr>
<tr>
<td>Product Index</td>
<td>20</td>
</tr>
</tbody>
</table>
ANTITHROMBIN

**COAMATIC® ANTITHROMBIN**

A chromogenic kit for the determination of antithrombin activity in human plasma. The use of factor Xa in preference to thrombin eliminates interference from heparin cofactor II and thrombin inhibitors.

**Measurement principle**

\[ \text{AT + Heparin} \rightarrow [\text{AT} \cdot \text{Heparin}] \\
[\text{AT} \cdot \text{Heparin}] + \text{FXa (excess)} \rightarrow [\text{AT} \cdot \text{Heparin} \cdot \text{FXa}] + \text{FXa (residual)} \\
\text{FXa (residual)} \rightarrow \text{Peptide + pNA} \]

**Reagents and their stability when opened**

- Substrate S-2765: 1 vial, 6 months, 2-8°C
- Buffer with heparin: 1 vial, 3 months, 2-8°C
- FXa: 1 vial, 3 months, 2-8°C

**Number of determinations**

- Test tube method: 50
- Microplate method: 200
- Automated methods: up to 130

**Article number: 82 1991 63**

---

**COAMATIC® LR ANTITHROMBIN**

A chromogenic kit for the determination of antithrombin activity in human plasma. The use of factor Xa in preference to thrombin eliminates interference from heparin cofactor II and thrombin inhibitors. Reagents in liquid formulation.

**Measurement principle**

\[ \text{AT + Heparin} \rightarrow [\text{AT} \cdot \text{Heparin}] \\
[\text{AT} \cdot \text{Heparin}] + \text{FXa (excess)} \rightarrow [\text{AT} \cdot \text{Heparin} \cdot \text{FXa}] + \text{FXa (residual)} \\
\text{FXa (residual)} \rightarrow \text{Peptide + pNA} \]

**Reagents and their stability when opened**

- Substrate S-2772: 2 vials, 6 months, 2-8°C
- Buffer with heparin: 1 vial, 3 months, 2-8°C
- FXa with heparin: 6 vials, 1 month, 2-8°C

**Number of determinations**

- Automated methods: up to 450

**Article number: 82 2957 63**

---

The Coamatic® Antithrombin kits are simple, accurate and convenient. All methods are based on FXa inhibition. Allows accurate determination of antithrombin in patients receiving heparin therapy. Superior reagent stability. Validated and documented protocols for automated instruments. Suitable for both large and small laboratories.
An APTT-based assay for the detection of the APC resistance phenotype, i.e. the poor anticoagulant response to activated protein C (APC). The test result (APC ratio) gives an estimation of the anticoagulant function in vivo and provides information on the thrombotic risk associated with inherited and acquired APC resistance.

**Measurement principle**
Plasma is incubated with the APTT reagent for a standard period of time. Coagulation is initiated by the addition of CaCl$_2$ in the absence and presence of APC and the time for clot formation is recorded.

**Reagents and their stability when opened**
- CaCl$_2$: 1x8 ml, 1 week 15-25°C, 1 month 2-8°C
- APTT reagent: 1x16 ml, 1 week 15-25°C, 1 month 2-8°C
- APC/CaCl$_2$: 4x2 ml, 8 hours 15-25°C, 5 days 2-8°C, 3 months -20°C

**Number of determinations**
Automated methods: 80-160

**Article number:** 82 2643 63

*Detects the APC resistance phenotype regardless of its cause. Detects both inherited and acquired APC resistance.*
**COATEST® APC™ RESISTANCE V**

An APTT-based kit for screening of factor V-related APC resistance. The high sensitivity and specificity of the test for the factor V:Q506 mutation is obtained by prediluting the sample plasma with an excess of V-DEF Plasma. The test design makes it possible to discriminate between heterozygous and homozygous factor V genotypes. It also allows for analysis of plasma from patients on heparin or oral anticoagulant therapy.

**Measurement principle**

One volume of plasma is prediluted with four volumes of V-DEF Plasma. The dilution is then incubated with the APTT reagent for a standard period of time. Coagulation is triggered by the addition of CaCl₂ in the absence and presence of exogenous APC and the time for clot formation is recorded.

**Reagents and their stability when opened**

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Amount</th>
<th>Stability Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>V-DEF Plasma</td>
<td>4x4 ml</td>
<td>8 hours: 15-25°C, 24 hours: 2-8°C, 3 months: -20°C</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>1x8 ml</td>
<td>1 week: 15-25°C, 1 month: 2-8°C</td>
</tr>
<tr>
<td>APTT reagent</td>
<td>1x16 ml</td>
<td>1 week: 15-25°C, 1 month: 2-8°C</td>
</tr>
<tr>
<td>APC/CaCl₂</td>
<td>4x2 ml</td>
<td>8 hours: 15-25°C, 5 days: 2-8°C, 3 months: -20°C</td>
</tr>
<tr>
<td>Control Plasma Level 1</td>
<td>1x1 ml</td>
<td>6 hours: 2-25°C, 3 months: -20°C</td>
</tr>
<tr>
<td>Control Plasma Level 2</td>
<td>1x1 ml</td>
<td>6 hours: 2-25°C, 3 months: -20°C</td>
</tr>
</tbody>
</table>

**Number of determinations** 80-160

**Article number:** 82 3120 63

---

**COATEST® APC™ RESISTANCE V-S**

An APTT-based kit for screening of factor V-related APC resistance. The high sensitivity and specificity of the test for the factor V:Q506 mutation is obtained by prediluting the sample plasma with an excess of V-DEF Plasma. The test design makes it possible to discriminate between heterozygous and homozygous factor V genotypes. It also allows for analysis of plasma from patients on heparin or oral anticoagulant therapy.

**Measurement principle**

One volume of plasma is prediluted with four volumes of V-DEF Plasma. The dilution is then incubated with the APTT reagent for a standard period of time. Coagulation is triggered by the addition of CaCl₂ in the absence and presence of exogenous APC and the time for clot formation is recorded.

**Reagents and their stability when opened**

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Amount</th>
<th>Stability Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>V-DEF Plasma</td>
<td>2x4 ml</td>
<td>8 hours: 15-25°C, 24 hours: 2-8°C, 3 months: -20°C</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>2x2 ml</td>
<td>1 week: 15-25°C, 1 month: 2-8°C</td>
</tr>
<tr>
<td>APTT reagent</td>
<td>2x4 ml</td>
<td>1 week: 15-25°C, 1 month: 2-8°C</td>
</tr>
<tr>
<td>APC/CaCl₂</td>
<td>2x2 ml</td>
<td>8 hours: 15-25°C, 5 days: 2-8°C, 3 months: -20°C</td>
</tr>
<tr>
<td>Control Plasma Level 1</td>
<td>1x1 ml</td>
<td>6 hours: 2-25°C, 3 months: -20°C</td>
</tr>
<tr>
<td>Control Plasma Level 2</td>
<td>1x1 ml</td>
<td>6 hours: 2-25°C, 3 months: -20°C</td>
</tr>
</tbody>
</table>

**Number of determinations** 40-80

**Article number:** 82 3138 63

---

**V-DEF PLASMA**

V-DEF Plasma is a prediluent of sample plasma to be used in conjunction with the use of Coatest™ APC™ Resistance V, and Coatest™ APC™ Resistance V-S. It strongly reduces the influence of plasma handling and storage, and provides a high discrimination for factor V-related APC resistance. In addition, V-DEF Plasma allows for analysis of plasma from patients on oral anticoagulant therapy or on heparin treatment (≤ 1IU/ml). V-DEF Plasma has a sufficiently high factor VIII activity to provide essentially normal APTT values.

**Reagents and their stability when opened**

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Amount</th>
<th>Stability Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>V-DEF Plasma</td>
<td>5x4 ml</td>
<td>8 hours: 15-25°C, 24 hours: 2-8°C, 3 months: -20°C</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>1x8 ml</td>
<td>1 week: 15-25°C, 1 month: 2-8°C</td>
</tr>
<tr>
<td>APTT reagent</td>
<td>1x16 ml</td>
<td>1 week: 15-25°C, 1 month: 2-8°C</td>
</tr>
<tr>
<td>APC/CaCl₂</td>
<td>4x2 ml</td>
<td>8 hours: 15-25°C, 5 days: 2-8°C, 3 months: -20°C</td>
</tr>
<tr>
<td>Control Plasma Level 1</td>
<td>1x1 ml</td>
<td>6 hours: 2-25°C, 3 months: -20°C</td>
</tr>
<tr>
<td>Control Plasma Level 2</td>
<td>1x1 ml</td>
<td>6 hours: 2-25°C, 3 months: -20°C</td>
</tr>
</tbody>
</table>

**Article number:** 82 3146 63

---

**High discrimination between genotypes with 100% sensitivity for FV:Q506. Reduces need for PCR determination. Applicable to anticoagulant treated patients.**
PROTEIN C

**COAMATIC® PROTEIN C**

A chromogenic kit for the determination of protein C activity in human plasma. No influence of heparin levels up to 3 IU/ml.

**Measurement principle**

Protein C → Protein C activator → Activated Protein C (APC)

S-2366 → APC → Peptide + pNA

**Reagents and their stability when opened**

- Substrate S-2366: 2 vials, 3 months, 2-8°C
- Protein C activator: 2 vials, 3 months, 2-8°C

**Number of determinations**

- Test tube method: 72
- Microplate method: 288
- Automated methods: up to 180

**Article number:** 82 2098 63

---

**PROTEIN S**

**COALIZA® PROTEIN S - FREE**

A kit for the quantitative determination of free protein S antigen in plasma.

**Measurement principle**

The Coaliza Protein S - Free kit method is based on a procedure described by Dahlbäck and colleagues (see Reference). The microplate wells are precoated with C4b-binding protein (C4BP), which has a very high affinity for binding free protein S (FPS) antigen in plasma. A monoclonal antibody (HPS 54) conjugated with the enzyme horseradish peroxidase (HRP) is added together with the plasma sample. After the sample and conjugate incubation, unbound material is washed away and bound protein S, in complex with C4BP is detected with the addition of a substrate-chromogen. The amount of colour in wells is directly proportional to the amount of free protein S antigen in the plasma sample. Reference: Tusar Kanti Giri, Andreas Hillarp, Yiva Härldig, Bengt Zöller, Björn Dahlbäck. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 79, 767-72 (1998).

**Reagents and their stability when opened**

- Microwell Strips: 12 x 8, exp. Date, 2-8°C
- Conjugate concentrate: 1 vial, exp. Date, 2-8°C
- Conjugate and Sample Diluent: 2 vials, exp. Date, 2-8°C
- Washing Buffer, Concentrate: 2 vials, exp. Date, 2-8°C
- Substrate Buffer: 2 vials, exp. Date, 2-8°C
- Chromogen TMB: 1 vial, exp. Date, 2-8°C
- Calibration Plasma: 2 vials, exp. Date, 2-8°C
- Normal Control Plasma: 1 vial, exp. Date, 2-8°C
- Stopping Solution: 1 bottle, exp. Date, 2-8°C

**Number of determinations**

- Test tube method: 96
- Microplate method: 288
- Automated methods: up to 180

**Article number:** 82 3567 63

---

**COMATIC® PROTEIN S - FREE**

Automated latex ligand immunoassay for the quantitative determination of free Protein S (PS) in human citrated plasma on automated instruments. Two forms of Protein S are present in plasma: free Protein S (40%), and Protein S linked to the complement C4b-binding protein (C4BP) (60%). Only free Protein S has functional cofactor activity.

**Measurement principle**

The presence of free Protein S in the sample is measured as the increase of turbidity produced by the agglutination of two latex reagents.

Purified C4BP adsorbed onto the first latex reagent reacts with a high affinity for free Protein S of patient plasma in the presence of Ca 2+ ions.

The free Protein S adsorbed on the C4BP latex triggers the agglutination reaction with the second latex reagent, which is sensitized with a monoclonal antibody directed against human Protein S. The degree of agglutination will be directly proportional to the free Protein S concentration in the test sample and is determined by measuring the decrease of the transmitted light at 405 nm caused by the aggregates.

**Reagents and their stability when opened**

- C4BP Buffer: 3 vials, exp. Date, 2-8°C
- C4BP Latex: 3 vials, 1 month, 2-8°C
- Anti PS MAb Latex: 3 vials, 1 month, 2-8°C

**Determinations/Kit**

Approximately 75 Tests

**Article number:** 82 4003 63
A chromogenic kit for the determination of factor VII activity in human plasma. Not affected by preactivation of factor VII.

**Measurement principle**

\[
\begin{align*}
\text{FX} & \xrightarrow{\text{Thromboplastin, Ca}^{2+}} \text{FXa} \\
\text{S-2765} & \xrightarrow{\text{FXa Peptide + pNA}} \\
\end{align*}
\]

**Reagents and their stability when opened**

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Quantity</th>
<th>Duration</th>
<th>Temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substrate S-2765</td>
<td>1 vial</td>
<td>6 months</td>
<td>2-8°C</td>
</tr>
<tr>
<td>BSA (Bovine Serum Albumin)</td>
<td>1 vial</td>
<td>1 week</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Buffer</td>
<td>1 vial</td>
<td>2 months</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Bovine FX</td>
<td>1 vial</td>
<td>1 week</td>
<td>2-8°C</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>1 vial</td>
<td>exp.date</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Thromboplastin</td>
<td>1 vial</td>
<td>1 month</td>
<td>2-8°C</td>
</tr>
</tbody>
</table>

**Number of determinations**

- Test tube method: 30
- Microplate method: 120
- Automated methods: up to 120

**Article number: 82 1900 63**

Coaset Factor VII is in compliance with the European Pharmacopoeia requirements.
A chromogenic kit for the determination of factor VIII activity in human plasma, blood fractions and purified preparations. Fulfills the requirements of the European Pharmacopoeia for factor VIII concentrate testing.

**Measurement principle**

Factor X $\rightarrow$ FIXa, Ca$^{2+}$, phospholipid $\rightarrow$ FXa $\rightarrow$ FVIII $\rightarrow$ S-2765 $\rightarrow$ FXaPeptide + pNA

**Reagents and their stability when opened**

- S-2765+I-2581: 1 vial, 3 months, 2-8°C
- Factor reagent: 2 vials, 1 day, 2-8°C, 1 month, -20°C
- Buffer: 1 vial, 1 month, 2-8°C

**Number of determinations**

- Test tube method: 30
- Microplate method: 120
- Automated methods: up to 100

**Article number:** 82 2585 63

---

A chromogenic kit for the determination of factor VIII activity in human plasma, blood fractions and purified preparations. Suitable for low volume testing.

**Measurement principle**

Factor X $\rightarrow$ FIXa, Ca$^{2+}$, phospholipid $\rightarrow$ FXa $\rightarrow$ FVIII $\rightarrow$ S-2765 $\rightarrow$ FXaPeptide + pNA

**Reagents and their stability when opened**

- S-2765+I-2581: 1 vial, 3 months, 2-8°C
- Factor reagent: 4 vials, 12 hours, 2-8°C, 3 months, -20°C
- Buffer: 1 vial, 3 months, 2-8°C
- Phospholipid: 1 vial, 3 months, 2-8°C

**Number of determinations**

- Test tube method: 4x20
- Microplate method: 240
- Automated methods: up to 200

**Article number:** 82 4094 63

---

A chromogenic kit for the determination of factor VIII activity in human plasma, blood fractions and purified preparations. Fulfills the requirements of the European Pharmacopoeia for factor VIII concentrate testing.

**Measurement principle**

Factor X $\rightarrow$ FIXa, Ca$^{2+}$, phospholipid $\rightarrow$ FXa $\rightarrow$ FVIII $\rightarrow$ S-2765 $\rightarrow$ FXaPeptide + pNA

**Reagents and their stability when opened**

- S-2765+I-2581: 1 vial, 3 months, 2-8°C
- Factor reagent: 2 vials, 12 hours, 2-8°C, 3 months, -20°C
- Buffer: 1 vial, 3 months, 2-8°C
- Phospholipid: 1 vial, 3 months, 2-8°C

**Number of determinations**

- Test tube method: 30
- Microplate method: 120
- Automated methods: up to 100

**Article number:** 82 4086 63

---

Co-lyophilisation of reagents for convenient handling.
Reliable tool for haemophilia classification.
No interference from heparin levels up to 1.5 IU/ml.

The Factor VIII kits have two measuring ranges. Validated and documented protocols for automated instruments.
All the Factor VIII kits can be used for the potency estimation of Factor VIII according to the European Pharmacopoeia requirements.
HEPARIN

**COAMATIC® HEPARIN**
A chromogenic kit for the determination of heparin and low molecular weight (LMW) heparin in human plasma. One-stage assay optimized for a wide range of instruments.

**Measurement principle**

\[
[\text{AT} \cdot \text{Heparin}] + \text{FXa} [\text{FXa} \cdot \text{AT} \cdot \text{Heparin}] 
\]

\[\text{S-2732} \quad \text{Peptide} + \text{pNA}\]

**Reagents and their stability when opened**

- Substrate S-2732: 2 vials, 6 months, 2-8°C
- Factor Xa: 2 vials, 3 months, 2-8°C

**Number of determinations**

- Test tube method: 50
- Microplate method: 200
- Automated methods: 120

**Article number:** 82 3393 63

---

**COATEST® LMW HEPARIN/HEPARIN**
A chromogenic kit for the determination of heparin and low molecular weight (LMW) heparin in human plasma. One-stage assay mainly intended for non-automated laboratories.

**Measurement principle**

\[
[\text{AT} \cdot \text{Heparin}] + \text{FXa} [\text{FXa} \cdot \text{AT} \cdot \text{Heparin}] 
\]

\[\text{S-2732} \quad \text{Peptide} + \text{pNA}\]

**Reagents and their stability when opened**

- Substrate S-2732: 1 vial, 6 months, 2-8°C
- Factor Xa: 1 vial, 1 month, 2-8°C
- Buffer: 1 vial, 2 months, 2-8°C
- LMWH standard: 1 vial, 6 months, 2-8°C

**Number of determinations**

- Test tube method: 50
- Microplate method: 125

**Article number:** 82 1363 63

---

**COATEST® HEPARIN**
A chromogenic kit for the determination of heparin and low molecular weight heparin in human plasma.

**Measurement principle**

\[
[\text{Heparin} + \text{AT (excess)}] [\text{Heparin} \cdot \text{AT}] + \text{FXa (residual)} [\text{Heparin} \cdot \text{AT} \cdot \text{FXa} + \text{FXa (residual)}] 
\]

\[\text{S-2222} \quad \text{Peptide} + \text{pNA}\]

**Reagents and their stability when opened**

- Substrate S-2222: 1 vial, 6 months, 2-8°C
- Factor Xa: 1 vial, 1 month, 2-8°C
- Antithrombin: 1 vial, 1 month, 2-8°C
- Buffer: 1 vial, 2 months, 2-8°C
- Normal plasma: 4 vials, 2 weeks, 2-8°C

**Number of determinations**

- Test tube method: 100
- Microplate method: 400
- Automated methods: up to 285

**Article number:** 25 5539 63

---

**Optimal user convenience by simple performance and few components. No sample dilution required. Validated and documented protocols for automated instruments.**

Optimized reaction system yields very consistent activity levels regardless of type of heparin. Independent of the antithrombin level of the patient. No addition of exogenous antithrombin required.

---

The heparin kits determine the antiFXa activity of LMW heparin and UF heparin. Excellent reagent stability. Suitable for both large and small laboratories.
COALIZA®
ANTI-CARDIOLIPIN IgG and IgM

An ELISA kit for the determination of IgG and IgM anti-cardiolipin (aCL) antibodies in human serum or plasma.

Measurement principle
The microplate strips are coated with cardiolipin used to capture aCL antibodies present in samples, controls and standards. Subsequently, antibodies specific for human IgG or IgM, labelled with horse-radish peroxidase (HRP), are added to the wells. These bind to any solid-phase cardiolipin bound antibody complex previously formed. Two enzyme-conjugated antibody solutions are provided – one for human IgG antibodies and one for human IgM antibodies. Concentrations of IgG aCL antibodies and IgM aCL antibodies must be determined separately. The bound enzyme-antibody conjugate is detected by the addition of tetramethyl-benzidine (TMB) and hydrogen peroxide (H₂O₂). Colour develops in proportion to the concentration of aCL antibodies.

Reagents and their stability when opened
- Microwell strips 12x8
- Sample diluent 1 vial
- GPL calibrator serum 3 vials
- MPL calibrator serum 3 vials
- GPL aCL positive control serum 1 vial
- MPL aCL positive control serum 1 vial
- Normal control serum 1 vial
- Conjugate anti-human IgG 1 vial
- Conjugate anti-human IgM 1 vial
- Substrate solution 1 vial
- Phosphate buffered saline (PBS) 1 vial
- Stopping solution 1 vial

Stability: exp. date 2-8°C

Number of determinations 96

Article number: 82 3377 63
COAMATIC® PLASMIN INHIBITOR

A novel chromogenic kit for the determination of plasmin inhibitor (α2-antiplasmin) activity in human plasma. No interference from α2-macroglobulin in the assay system.

Measurement principle
Plasmin Inhibitor + Plasmin (excess) (Plasmin Inhibitor • Plasmin) + Plasmin (residual)
S-2403 Plasmin (residual) Peptide + pNA

Reagents and their stability when opened
Substrate S-2403 1 vial 6 months 2-8°C
Plasmin solvent 1 vial exp. date
Buffer stock solution 2 vials exp. date
Plasmin 1 vial 1 month 2-8°C

Number of determinations
Microplate method 200
Test tube method 50
Automated methods 125-200

Article number: 82 3187 63

COAMATIC® PLASMINOGEN

A chromogenic kit for the determination of plasminogen activity in human plasma. Addition of plasminogen-free fibrinogen to the streptokinase reagent overcomes the over estimation of plasminogen which may arise in patients with elevated levels of FDP or fibrinogen.

Measurement principle
Plg + Sk/Fib [Plg • Sk/Fib]
S-2403 [Plg • Sk/Fib] Peptide + pNA

Reagents and their stability when opened
Substrate S-2403 2 vials 6 months 2-8°C
Streptokinase/fibrinogen 2 vials exp. date
Buffer stock solution 2 vials exp. date
Plasmin 1 vial 1 month 2-8°C

Number of determinations
Test tube method 50
Microplate method 200
Automated methods up to 200

Article number: 82 2452 63

No interference from other plasmin inhibitors.
Validated and documented protocols for automated instruments.
**CALIBRATION PLASMA-LMW HEPARIN**

**Composition**
Lyophilised human plasma, prepared by addition of heparin. Calibrated against the 1st International WHO standard (LMW heparin).

**Application**
For construction of calibration curves for use in chromogenic heparin assays.

**Package**
calibrator 1  4x1 ml
calibrator 2  4x1 ml
calibrator 3  4x1 ml

**Article number:** 82 3500 63

---

**CONTROL PLASMA-LMW HEPARIN**

**Composition**
Lyophilised human plasma prepared by addition of LMW heparin. Calibrated against the 1st International WHO standard (LMW heparin).

**Application**
Quality control of chromogenic heparin assays.

**Package**
Low  4x1 ml
High  4x1 ml

**Article number:** 82 3492 63

---

**CONTROL PLASMA LEVEL 1 COATEST® APC™ RESISTANCE**

**Composition**
Lyophilised citrated, stabilised human plasma prepared from pools of plasma collected from healthy donors.

**Application**
Quality control of Coatest® APC™ Resistance and Coatest® APC™ Resistance V.

**Package**
5x1 ml

**Article number:** 82 2650 63

---

**CONTROL PLASMA LEVEL 2 COATEST® APC™ RESISTANCE**

**Composition**
Lyophilised citrated, stabilised human plasma prepared from pools of plasma collected from donors carrying the Factor V.Q506 mutation.

**Application**
Quality control of Coatest® APC™ Resistance and Coatest® APC™ Resistance V.

**Package**
5x1 ml

**Article number:** 82 2668 63
**ANTITHROMBIN 10 IU**

**Composition and purity**
Lyophilised powder prepared from human plasma after affinity chromatography on heparin-Sepharose gel. Contains human albumin as a stabiliser.

**Included in** Coatest® Heparin

**Package** 10x10 IU

*Note: This preparation is not a standard.*

**Article number:** 82 0720 39

---

**PLASMINOGEN**

**Composition and purity**
Lyophilised powder of human plasminogen prepared from Cohn supernatant by affinity chromatography. At least 95% of the plasminogen content is Glu-plasminogen. Contains lysine, sodium chloride and glucose.

**Specific activity**
20-40 CU/vial (batch specific).

**Application**
Determination of streptokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI) and soluble fibrin.

**Package** 1x1.5 mg

**Article number:** 81 0663 39

---

**FXa**

**Composition and purity**
Lyophilised powder prepared from bovine plasma and purified by barium citrate adsorption and liquid chromatography. Contains buffer salts, albumin and polyethylene glycol. The activity (71 nkat) is determined with the substrate S-2222.

**Included in** Coatest® Heparin

**Package** 10x71 nkat

**Article number:** 82 0985 39

---

**ANTITHROMBIN 25 IU**

**Composition and purity**
Lyophilised powder prepared from human plasma after affinity chromatography on heparin-Sepharose gel. Pure preparation, does not contain stabiliser.

**Package** 1x25 IU

*Note: This preparation is not a standard.*

**Article number:** 81 0796 39
CHROMOGENIC SUBSTRATES

S-2222™
Chromogenic substrate for factor Xa.
Package 25 mg
Article number: 82 0316 39

S-2238™
Chromogenic substrate for thrombin.
Package 25 mg
Article number: 82 0324 39

S-2251™
Chromogenic substrate for plasmin and streptokinase-activated plasminogen.
Package 25 mg
Article number: 82 0332 39

S-2266™
Chromogenic substrate for glandular kallikreins and factor XIa.
Package 25 mg
Article number: 82 0480 39

S-2222
Formula: Bz-Ile-Glu(γ-OR)-Gly-Arg-pNA•HCl
R=H (50%) and R=CH₃ (50%)
Molecular weight: 741.3

S-2238
Formula: H-D-Phe-Pip-Arg-pNA•2HCl
Molecular weight: 625.6

S-2251
Formula: H-D-Val-Leu-Lys-pNA•2HCl
Molecular weight: 551.6

S-2266
Formula: H-D-Val-Leu-Arg-pNA•2HCl
Molecular weight: 579.6
CHROMOGENIC SUBSTRATES

S-2288™
Chromogenic substrate for t-PA and a broad spectrum of other serine proteases.
Package 25 mg
Article number: 82 0852 39

S-2302™
Chromogenic substrate for plasma kallikrein and factor Xlla.
Package 25 mg
Article number: 82 0340 39

S-2366™
Chromogenic substrate for activated protein C and factor Xlla.
Package 25 mg
Article number: 82 1090 39

S-2403™
Chromogenic substrate for plasmin and streptokinase-activated plasminogen.
Package 25 mg
Article number: 82 2254 39

S-2288
Formula: H-D-Ile-Pro-Arg-pNA•2HCl
Molecular weight: 577.6

S-2302
Formula: H-D-Pro-Phe-Arg-pNA•2HCl
Molecular weight: 611.6

S-2366
Formula: pyroGlu-Pro-Arg-pNA•HCl
Molecular weight: 539.0

S-2403
Formula: pyroGlu-Phe-Lys-pNA•HCl
Molecular weight: 561.0
CHROMOGENIC SUBSTRATES

S-2444™

Chromogenic substrate for urokinase.

Package 25 mg

Article number: 82 0357 39

S-2765™

Chromogenic substrate for factor Xa.

Package 25 mg

Article number: 82 1413 39

S-2444

Formula: pyroGlu-Gly-Arg-pNA•HCl
Molecular weight: 498.9

S-2765

Formula: Z-D-Arg-Gly-Arg-pNA•2HCl
Molecular weight: 714.6
SCHEMATIC VIEW OF THE HAEMOSTATIC SYSTEM

The coagulation cascade

**Intrinsic pathway**
- HMW kininogen prekallikrein FXIIa
- FXI → FXIa → Ca2+
- FIXa → FXa → Ca2+
- FVIIIa → FXa → Pl, Ca2+

**Extrinsic pathway**
- TF/FVIIa
- FXa → Ca2+
- FX, FIX → Ca2+
- FVIII, FV → Ca2+

**The fibrinolytic system**
- Plasminogen → Plasmin
- u-PA, t-PA
- Plasmin Inhibitor
- FXIIIa → FXIII
- XL-Fibrin → Fibrin Monomer → XL-FDP

**Abbreviations**
- F = factor
- a = active
- TM = thrombomodulin
- PL = phospholipid
- HMW = high molecular weight
- APC = activated protein C
- XL = crosslinked
- FDP = fibrin degradation products
## PRODUCT INDEX

<table>
<thead>
<tr>
<th>Description</th>
<th>510 (K) clearance*</th>
<th>Art. No.</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Cardiolipin</td>
<td></td>
<td>82 3377 63</td>
<td>12</td>
</tr>
<tr>
<td>Antithrombin</td>
<td>Yes</td>
<td>82 1991 63</td>
<td>5</td>
</tr>
<tr>
<td>APC™ Resistance</td>
<td>Yes</td>
<td>82 2643 63</td>
<td>6</td>
</tr>
<tr>
<td>Factor VII</td>
<td>Yes</td>
<td>82 1900 63</td>
<td>9</td>
</tr>
<tr>
<td>Factor VIII</td>
<td>Yes</td>
<td>82 2585 63</td>
<td>10</td>
</tr>
<tr>
<td>Heparin</td>
<td>Yes</td>
<td>82 3393 63</td>
<td>11</td>
</tr>
<tr>
<td>Plasmin Inhibitor</td>
<td>Yes</td>
<td>82 3187 63</td>
<td>13</td>
</tr>
<tr>
<td>Plasminogen</td>
<td>Yes</td>
<td>82 2452 63</td>
<td>13</td>
</tr>
<tr>
<td>Protein C</td>
<td>Yes</td>
<td>82 2098 63</td>
<td>8</td>
</tr>
<tr>
<td>Protein S</td>
<td>Yes</td>
<td>82 3567 63</td>
<td>8</td>
</tr>
</tbody>
</table>

* This is the 510 (K) clearance status at time of printing. Please contact your local distributor for updated information.
While others are still exploring chromogenic products, we’re creating the next generation.

**COAMATIC®**

The latest techniques designed specifically for use with automated instruments.

**COATEST®**

Innovative and well-documented products with a wide range of applications for automated instruments.

**COASET®**

Products designed for research applications.

**COALIZA®**

Complete ELISA-based kits for antigen determinations.